This is a pilot study that explores whether higher initial doses of risankizumab (300 mg and
600 mg, 2 times and 4 times the standard initial doses for plaque psoriasis) can more
effectively target resident memory T cells, a type of immune cell within psoriatic lesions,
and whether this results in higher levels of completely clear skin and for longer periods of
time following withdrawal of drug. It is believed that resident memory T cells in psoriatic
skin contribute to the persistence of psoriasis. It is believed that if the study drug can
more effectively eliminate these cells, better clearance of psoriasis may be achieved (when
compared to standard initial doses of study drug).